First-Line Drugs for Respiratory Diseases in Pediatrics

Asthma Management

The American Academy of Allergy, Asthma, and Immunology recommends low-dose inhaled corticosteroids as the preferred therapy for children 5 years and older with mild persistent asthma 1
For children younger than 5 years with persistent asthma, the American Academy of Allergy, Asthma, and Immunology recommends low-dose inhaled corticosteroids delivered via nebulizer, dry powder inhaler (DPI), or metered-dose inhaler (MDI) with holding chamber (with or without face mask) 1
Alternative therapies for mild persistent asthma include cromolyn, leukotriene receptor antagonists (LTRAs), nedocromil, or sustained-release theophylline, as suggested by the American Academy of Allergy, Asthma, and Immunology 1

Pneumonia Management

The Infectious Diseases Society of America recommends amoxicillin (50-75 mg/kg/day in 2 doses) as the preferred oral therapy for mild community-acquired pneumonia caused by Streptococcus pneumoniae 2
For Haemophilus influenzae infections (if β-lactamase negative), the Infectious Diseases Society of America recommends amoxicillin (75-100 mg/kg/day in 3 doses) 2
For β-lactamase producing H. influenzae, the Infectious Diseases Society of America recommends amoxicillin-clavulanate (amoxicillin component 45 mg/kg/day in 3 doses or 90 mg/kg/day in 2 doses) 2
For Mycoplasma pneumoniae or Chlamydophila pneumoniae infections, the Infectious Diseases Society of America recommends azithromycin as the preferred therapy (10 mg/kg on day 1, followed by 5 mg/kg/day once daily on days 2-5) 2
Alternative treatments for atypical pneumonia include clarithromycin (15 mg/kg/day in 2 doses) or oral erythromycin (40 mg/kg/day in 4 doses), as suggested by the Infectious Diseases Society of America 2

Acute Asthma Exacerbations

The British Thoracic Society recommends high-flow oxygen via face mask for immediate treatment of acute severe asthma 3
The British Thoracic Society suggests salbutamol 5 mg or terbutaline 10 mg via oxygen-driven nebulizer (half doses for very young children) for immediate treatment of acute severe asthma 3
The British Thoracic Society recommends intravenous hydrocortisone for immediate treatment of acute severe asthma 3
The British Thoracic Society suggests adding ipratropium 100 mg nebulized every 6 hours for immediate treatment of acute severe asthma 3
The British Thoracic Society recommends monitoring for life-threatening asthma features, including PEF <33% predicted or best, poor respiratory effort 3
The British Thoracic Society recommends monitoring for life-threatening asthma features, including cyanosis, silent chest, fatigue or exhaustion 3
The British Thoracic Society recommends monitoring for life-threatening asthma features, including agitation or reduced level of consciousness 3

Dexamethasone for Pediatric Wheezing

Age-Specific Guidelines and Approvals

The American Academy of Allergy, Asthma, and Immunology recommends dexamethasone for acute asthma exacerbations in pediatric patients as young as 1 year of age, though the evidence specifically supports systemic corticosteroids primarily for acute asthma exacerbations rather than routine wheezing management 4, 5
The FDA has approved inhaled corticosteroids, the preferred long-term therapy, starting at 1 year of age with budesonide nebulizer solution, for children 1-8 years 6, 7

Chronic and Acute Management

For chronic or recurrent wheezing, inhaled corticosteroids, not dexamethasone, are preferred starting at age 1 year with budesonide nebulizer solution 6, 7, 5
For acute severe exacerbations, systemic corticosteroids including dexamethasone can be used at any age when clinically indicated, with a single dose of oral dexamethasone (0.3 mg/kg) being noninferior to 3 days of prednisolone for acute asthma exacerbations 4, 5

Diagnostic Considerations

For children under 5 years with recurrent wheezing, consider initiating long-term control therapy only when specific criteria are met, including ≥4 wheezing episodes in the past year and a positive asthma predictive index 4, 8, 5
The American Academy of Pediatrics and the American Academy of Allergy, Asthma, and Immunology suggest that not all wheezing equals asthma requiring steroids, especially in children under 3 years where viral infections are the most common cause 4, 8, 5

Management of Persistent Wheezing in Pediatric Patients

Immediate Pharmacologic Management

The American Thoracic Society recommends adding ipratropium bromide (100-500 mcg nebulized every 6 hours) for pediatric patients with persistent wheezing despite salmeterol/fluticasone therapy, while simultaneously pursuing diagnostic evaluation to identify underlying anatomic abnormalities or alternative diagnoses 9
For pediatric patients with persistent wheezing, continue high-flow oxygen if oxygen saturation is less than 92% 9
Increase the frequency of short-acting beta-agonist (albuterol/salbutamol) to every 15-30 minutes if the patient is not improving 9
Administer oral prednisolone (1-2 mg/kg/day, maximum 40 mg) for moderate to severe wheezing in pediatric patients 9
Intravenous hydrocortisone may be considered if life-threatening features are present, such as PEF less than 33% predicted, cyanosis, silent chest, or altered consciousness 9

Diagnostic Evaluation for Persistent Symptoms

Approximately 33% of children with persistent wheezing despite standard therapy have an identifiable anatomic abnormality, according to the American Thoracic Society 10, 11
Flexible fiberoptic bronchoscopy with airway survey is recommended to identify tracheomalacia, bronchomalacia, vascular rings, or airway compression in pediatric patients with persistent wheezing 10, 11
Bronchoalveolar lavage (BAL) during bronchoscopy may be considered, as 40-60% of children with persistent wheezing may have positive BAL cultures indicating bacterial infection 10, 11
A video-fluoroscopic swallowing study may be recommended to evaluate for aspiration contributing to wheezing in pediatric patients 10, 11

Glucocorticoid Treatment for Children Over 2 Years with Wheezing

Primary Recommendation

The American Academy of Allergy, Asthma, and Immunology recommends daily low-dose inhaled corticosteroids as the preferred first-line controller therapy for children older than 2 years with persistent asthma or recurrent wheezing, demonstrating superior efficacy in reducing symptoms, exacerbations, and improving quality of life compared to alternative medications 12

Treatment Algorithm by Disease Severity

For children older than 2 years with mild persistent asthma, the American Academy of Pediatrics recommends initiating daily low-dose inhaled corticosteroids as the preferred option, delivered via nebulizer, dry powder inhaler, or metered-dose inhaler with holding chamber 12
The American Thoracic Society suggests considering a leukotriene receptor antagonist (LTRA) trial in children ≥2 years when inhaled medication delivery is suboptimal due to poor technique or adherence issues 12

Moderate Persistent Asthma

The National Asthma Education and Prevention Program recommends two preferred treatment options: adding long-acting inhaled beta2-agonists to low-dose inhaled corticosteroids or increasing inhaled corticosteroid dose to medium range as monotherapy, with the strength of evidence showing combination therapy superiority and lower corticosteroid exposure 12, 13

Critical Monitoring and Response Assessment

The American College of Allergy, Asthma, and Immunology recommends establishing clear treatment endpoints, including attempting step-down therapy if sustained benefits occur for 2-4 months, with a strength of evidence showing effectiveness in reducing symptoms and exacerbations 12, 13
If no clear benefits within 4-6 weeks, the guideline suggests discontinuing therapy and considering alternative diagnoses or treatments, with a moderate strength of evidence supporting this approach 12, 13

Growth and Safety Profile

The American Academy of Pediatrics notes that the potential risk of delayed growth from inhaled corticosteroids is well balanced by their effectiveness in improving health outcomes, with a high strength of evidence supporting their use 12, 13
The guideline also states that side effects appear dose-related, demonstrated at medium-dose range, supporting use of lowest effective dose, with a moderate strength of evidence supporting this approach 12, 13

Budesonide Inhaler Dosing and Management in Pediatric Asthma

Age‑Specific Dosing and Device Selection

Budesonide inhalation suspension (Pulmicort Respules) is FDA‑approved for children starting at 12 months of age and is delivered via nebulizer with a face mask or mouthpiece. 14
For children < 4 years who cannot coordinate inhalation, a nebulizer with budesonide suspension should be used rather than a dry‑powder inhaler (DPI) or metered‑dose inhaler (MDI). 14
Children ≥ 4 years with adequate inhalation technique may use a DPI (e.g., fluticasone, approved ≥ 4 years) or an MDI with a holding chamber. 14

Treatment Options for Moderate Persistent Asthma

In children ≥ 4 years with moderate persistent asthma, adding a long‑acting β₂‑agonist (salmeterol) to low‑dose budesonide is preferred because it achieves control with lower total corticosteroid exposure. [14][15]
No safety or efficacy data support LABA use in children < 4 years; therefore, medium‑dose budesonide monotherapy (e.g., 0.5 mg BID nebulized or up to 400 µg daily DPI/MDI) is the recommended option for this age group. [14][16]
Two evidence‑based strategies are available for moderate persistent asthma:
Comparative trials consistently favor the LABA‑addition approach over dose escalation of budesonide because systemic adverse effects increase with medium‑to‑high inhaled corticosteroid doses. [16][15]

Monitoring, Assessment, and Dose Titration

Clinical response to budesonide should be evaluated within 4–6 weeks; lack of clear benefit warrants discontinuation and consideration of alternative therapy. 16
When control is sustained for 2–4 months, a step‑down to the lowest effective dose is recommended. 16
The titration principle emphasizes using the minimum dose that maintains asthma control, as adverse effects are dose‑related. 17

Safety and Growth Considerations

Long‑term budesonide at 200 µg daily in children < 11 years is associated with an average reduction in linear growth of ~1.3 cm over three years, with the greatest decrement (~0.6 cm) occurring in the first year. 18
Despite this modest growth effect, the benefit of reduced exacerbations and improved control balances the risk, and most children on chronic inhaled corticosteroids achieve their predicted adult height. 18
Systemic effects, including potential adrenal suppression, become more likely with medium‑to‑high inhaled corticosteroid doses, reinforcing the recommendation to use the lowest effective dose. 16

Pharmacologic Pitfalls and Correct Practices

LABAs must never be prescribed as monotherapy in children; they should always be combined with an inhaled corticosteroid. 15
Premature escalation of therapy before the 4–6‑week response assessment is a common error; the correct pathway is to start low‑dose budesonide, assess response, then step up or step down as needed. [16][17]

Role of Leukotriene Receptor Antagonists (LTRAs)

LTRAs (e.g., montelukast) are an alternative when inhaled delivery is problematic, but they are generally less effective than inhaled corticosteroids across most clinical outcomes. [19][20]
Montelukast chewable 4 mg tablets are approved for children aged 2–6 years. 14